Oncological outcomes of radical nephroureterectomy for upper urinary tract urothelial neoplasia in Denmark

Azawi, Nessn; Næraa, Sara Haunstrup; Subhi, Yousif; Vásquez, Juan Luis; Norus, Thomas; Dahl, Claus; Thind, Peter; Jensen, Jørgen Bjerggaard

doi:10.1080/21681805.2019.1710562

Cited by 10 publications

(4 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The small sample size in the single-center study is a notable limitation, and 16 patients were not included in the final recurrence analysis due to prior bladder cancer, which bladder recurrences can be attributed to and not UTUC; therefore, the recurrence analysis is hypothesis generating and not comparable with the aforementioned prospective ODMIT-C trial. Furthermore, there were significant differences in tumor stage and grade between the two groups, which can influence the BRRs, and the median follow-up time of 16 mo causes the possibility of missed bladder recurrences, as we know from prior studies that 85% of recurrences occur in the first 3 yr postoperatively [4] . Future studies calls for prospective, well-powered, multicenter randomized controlled trials with standardized timing of intravesical instillation of MMC in order to demonstrate a significant decrease in BRR.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Intraoperative Mitomycin C Bladder Instillation During Radical Nephroureterectomy Is Feasible and Safe

Nadler

Oedorf

Jensen

et al. 2021

European Urology Open Science

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

“…After radical treatment of UTUC, intravesical recurrence occurs in 22–47% of cases [2] , [3] . In a large Danish cohort, the incidence of intravesical recurrence was 21%, and 85% of recurrences occurred within the first 2 yr after operation [4] .…”

Section: Introductionmentioning

confidence: 99%

Intraoperative Mitomycin C Bladder Instillation During Radical Nephroureterectomy Is Feasible and Safe

Nadler

Oedorf

Jensen

et al. 2021

European Urology Open Science

Self Cite

View full text Add to dashboard Cite

show abstract

“…Other large nonspecific cancer registries have been utilised internationally to contribute to the UTUC literature. Scandinavian countries including Denmark (21,22), Norway (2), Iceland (23), and The Netherlands (24) have all contributed to the UTUC literature utilising large cancer and admission based registries. Other European nations have also utilised registry based data to contribute to their understanding of UTUC including Spain (25), Croatia (26), and The United Kingdom via the National Cancer Repository (27).…”

Section: International General Registriesmentioning

confidence: 99%

The utility of clinical registries for guiding clinical practice in upper tract urothelial cancer: a narrative review

Kealey¹,

Snider²,

Hayne³

et al. 2023

Transl Androl Urol

View full text Add to dashboard Cite

Background and Objective: Upper tract urothelial cancer (UTUC) lacks high-quality evidence to appraise current patterns of presentation, diagnosis, treatment and outcomes as a result of disease rarity and patient heterogeneity. Registries may overcome many of the challenges making clinical trials challenging in UTUC and provide answers to many of the clinical questions that afflict UTUC management. In this narrative review we aim to summarise the design of registries that have contributed to the UTUC literature, discuss their strengths and limitations and the future directions of registries in UTUC.Methods: Two independent reviewers conducted a search of the OVID MEDLINE database from July 2002-July 2022. Included articles were required to be published in peer reviewed journals and use registrybased methodology to report on UTUC. Search was limited by MeSH and key words and was limited to the English language.Key Content and Findings: One hundred and forty-four articles were identified and included as reporting on UTUC from a registry-based methodology. Articles utilising registry-based data have substantially increased over the study period with the majority of articles arising from large generalised cancer databases in North America. There has been an increase in UTUC-specific registries in the previous five years that have offered the most granular, complete analysis and these will continue to report in the coming years. The majority of published data assessed epidemiological factors and compared outcomes of treatment modalities with a small proportion of articles focusing on prognostic nomograms and quality of life. Larger cancer registries that contribute the majority of the published analysis are likely subject to significant selection bias when comparing cohorts for treatment analysis and the need for prospective UTUC specific registries is apparent. Future directions include the potential for registry-based randomised controlled trials (RCTs) and clinical quality registries (CQR) that have the ability to change practice and improve care. Conclusions:The utilisation of registry-based methodology for analysis in UTUC has increased substantially over the last 20 years. In addition to the utilisation of large cancer registries, the creation of UTUC specific registries is likely to contribute the most granular, translatable data in diagnosis and management.

show abstract

“…A shorter interval between IVR and UTUC is considered indicative of a poorer prognosis [12]. Moreover, the period of 2-2.5 years post-surgery is considered a high-risk phase for IVR, highlighting the importance of implementing adjuvant therapies in conjunction with surgery to reduce IVR [13][14][15][16][17]. This aspect not only warrants significant attention but also necessitates further research and investigation.…”

Section: Introductionmentioning

confidence: 99%

Intravesical Therapy for Upper Urinary Tract Urothelial Carcinoma: A Comprehensive Review

Wang,

Shi,

et al. 2023

Cancers

View full text Add to dashboard Cite

Upper tract urothelial carcinoma (UTUC) poses unique challenges in diagnosis and treatment. This comprehensive review focuses on prophylactic intravesical therapy for UTUC, summarizing key aspects of intravesical therapy in various clinical scenarios, including concurrent with or following radical nephroureterectomy, kidney-sparing surgery, ureteroscopy-guided biopsy. The incidence of intravesical recurrence in UTUC after surgical treatment is significant, necessitating effective preventive measures. Intravesical therapy plays a vital role in reducing the risk of bladder recurrence following UTUC surgery. Tailoring timing, drug selection, dosage, and frequency is vital in optimizing treatment outcomes and reducing intravesical recurrence risk in UTUC. This review provides a comprehensive summary of the history, clinical trials, guideline recommendations, and clinical applications of intravesical therapy for UTUC. It also discusses the future directions based on current clinical needs and ongoing trials. Future directions entail optimizing dosage, treatment duration, and drug selection, as well as exploring novel agents and combination therapies. Intravesical therapy holds tremendous potential in improving outcomes for UTUC patients and reducing the risk of bladder recurrence. Although advancements have been made in UTUC treatment research, further refinements are necessary to enhance efficacy and safety.

show abstract

Oncological outcomes of radical nephroureterectomy for upper urinary tract urothelial neoplasia in Denmark

Cited by 10 publications

References 29 publications

Intraoperative Mitomycin C Bladder Instillation During Radical Nephroureterectomy Is Feasible and Safe

Intraoperative Mitomycin C Bladder Instillation During Radical Nephroureterectomy Is Feasible and Safe

The utility of clinical registries for guiding clinical practice in upper tract urothelial cancer: a narrative review

Intravesical Therapy for Upper Urinary Tract Urothelial Carcinoma: A Comprehensive Review

Contact Info

Product

Resources

About